Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012;67(3):283-7.
doi: 10.6061/clinics/2012(03)14.

Assessing the benefits of rosiglitazone in women with polycystic ovary syndrome through its effects on insulin-like growth factor 1, insulin-like growth factor-binding protein-3 and insulin resistance: a pilot study

José Gomes Batista  1 , José Maria Soares Jr, Carla Cristina Maganhin, Ricardo Santos Simões, Geraldez Tomaz, Edmund Chada Baracat
Affiliations
Randomized Controlled Trial

Assessing the benefits of rosiglitazone in women with polycystic ovary syndrome through its effects on insulin-like growth factor 1, insulin-like growth factor-binding protein-3 and insulin resistance: a pilot study

José Gomes Batista et al. Clinics (Sao Paulo). 2012.
No abstract available

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported.

Figures

Figure 1
Figure 1
Study fluxogram.
Figure 2
Figure 2
Pearson's correlation between insulin resistance and IGF-1 and IGFPB-3. A – Correlation of HOMA-IR values before vs. after treatment in the control group; B - Correlation of HOMA-IR values before vs. after treatment in the rosiglitazone group; C – Correlation of HOMA-IR values with IGF-1 levels before treatment in the control group; D - Correlation of HOMA-IR and IGF-1 levels before treatment in the rosiglitazone group; E - Correlation of HOMA-IR values with IGF-1 levels after treatment in the control group; F - Correlation of HOMA-IR values with IGF-1 levels after treatment in the rosiglitazone group; G - Correlation of HOMA-IR values with IGFPB-3 levels before treatment in the control group; H - Correlation of HOMA-IR values with IGFPB-3 levels before treatment in the rosiglitazone group; I - Correlation of HOMA-IR values with IGFPB-3 levels after treatment in the control group; J - Correlation of HOMA-IR values with IGFPB-3 levels after treatment in the rosiglitazone group.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Legro RS, Gnatuk CL, Kunselman AR, Dunaif A. Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab. 2005;90:3236–42. - PubMed
    1. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2010;1:CD003053. - PubMed
    1. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91:456–88. - PubMed
    1. Jensterle M, Sebestjen M, Janez A, Prezelj J, Kocjan T, Keber I, et al. Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome. Eur J Endocrinol. 2008;159:399–406. - PubMed
    1. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8:41. - PMC - PubMed

Publication types

MeSH terms

Substances